Last reviewed · How we verify
Victoza
At a glance
| Generic name | Victoza |
|---|---|
| Also known as | Liraglutide, Victoza®, Liraglutide, daily SC injection |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Target | Glucagon-like peptide 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 2
- Weight loss
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Headache
- Nasopharyngitis
- Dyspepsia
- Upper Respiratory Tract Infection
- Constipation
- Back Pain
Serious adverse events
- Severe gastrointestinal adverse reactions
- Withdrawals due to gastrointestinal adverse reactions
- Injection site reactions
- Hypoglycemia requiring assistance of another person
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
- Effects of GH and Lirglutide on AgRP (PHASE4)
- Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |